

# **SAFETY DATA SHEET**

| Section 1: Identification                            |  |  |
|--|--|--|
| Material   | Dwgglowide tehlets Img and 2 mg  |  |
|  | Prucalopride tablets 1mg and 2 mg  |  |
| Recommended use                                      | Treatment of major depressive disorder (MDD)   |  |
| Manufacturer   | Annora Pharma Private Limited, Survey No. 261,<br>Annaram Village, Gummadidala Mandal, Sanga Reddy,<br>Telangana 502313, India (IND) |  |
| Distributor  | Camber Pharmaceuticals, Inc., Piscataway, NJ 08854   |  |
| Section 2  | : Hazard(s) Identification   |  |
| Classification Classification according to WHIMIS    |  |  |
| Acute toxicity - Oral Category 4                     | Category 4   |  |
| Chronic aquatic toxicity                             | Category 3   |  |
| Hazard statements Classification according to WHIMIS |  |  |
| <b>Precautionary Statements - Prevention</b>         | Wash face, hands and any exposed skin thoroughly after handling. Do not eat, drink or smoke when using this product                  |  |
| Precautionary Statements - Response                  |  |  |
| Ingestion  | Call a POISON CENTER or doctor if you feel unwell Rinse mouth  |  |
| Precautionary Statements - Disposal                  | Dispose of contents and container to an approved waste disposal plant  |  |
| Other information                                    | No information available.  |  |
| Section 3: Compo                                     | osition/Information on Ingredients   |  |
| Ingredients  | CAS  |  |
| Prucalopride Succinate                               | 179474-85-2  |  |
| Microcrystalline cellulose                           | 9004-34-6  |  |
| Lactose monohydrate                                  | 10039-26-6   |  |
| Colloidal silicon dioxide                            | 7631-86-9  |  |
| Magnesium Stearate                                   |  |  |
| Opadry II White                                      | NA   |  |
| Opadry II Yellow                                     | NA   |  |



|   | / 11111010  |  |
|---|---|--|
| Sect  | ion 4: First-Aid Measures   |  |
| Description of first aid measures                                   |   |  |
| General advice  | Show this safety data sheet to the doctor in attendance   |  |
| Inhalation  | Remove to fresh air.  |  |
| Eye contact   | Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a doctor. |  |
| Skin contact  | Wash skin with soap and water.  |  |
| Ingestion   | Do Not induce vomiting. Rinse mouth. Never give anything by mouth to an unconscious person. Call a doctor         |  |
| Most important symptoms and effects                                 | , both acute and delayed  |  |
| Symptoms  | No information available  |  |
| Indication of any immediate medical a                               | ttention and special treatment needed   |  |
| Note to doctors   | Treat symptomatically   |  |
| Section 5: Fire-Fighting Measures                                   |   |  |
| Suitable extinguishing media  | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.           |  |
| Large Fire  | CAUTION: Use of water spray when fighting fire may be inefficient   |  |
| Unsuitable extinguishing media                                      | Do not scatter spilled material with high pressure water streams.   |  |
| Specific hazards arising from the                                   | No information available  |  |
| chemical  |   |  |
| Explosion data  |   |  |
| Sensitivity to mechanical impact                                    | None.   |  |
| Sensitivity to static discharge                                     | None.   |  |
| Special protective equipment and                                    | Firefighters should wear self-contained breathing   |  |
| precautions for fire-fighters                                       | apparatus and full firefighting turnout gear. Use personal protection equipment                                   |  |
| Section 6: Accidental Release Measures                              |   |  |
| Personal precautions, protective equipment and emergency procedures |   |  |
| Personal precautions  | Ensure adequate ventilation.  |  |
| Methods and material for containmen                                 | t and cleaning up   |  |
| Methods for cleaning up   | Pick up and transfer to properly labelled containers  |  |
|   |   |  |



|   | 7 11 10 10   |  |
|---|--|--|
| Sectio                                      | on 7: Handling and Storage Section   |  |
| Conditions for safe storage, includin       | g any incompatibilities  |  |
| Storage Conditions                          | Store prucalopride tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (between 59°F to 86°F) [see USP Controlled Room Temperature].                   |  |
|   | Store prucalopride tablets in the original container to protect from moisture.   |  |
| 8. Expo                                     | osure controls / personal protection   |  |
| Control parameters                          |  |  |
| Exposure Limits                             | This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region-specific regulatory bodies                           |  |
| Appropriate engineering Controls            |  |  |
| Engineering controls                        | Showers Eyewash stations Ventilation systems   |  |
| Individual protection measures, sucl        | n as personal protective equipment   |  |
| Eye/face protection                         | Avoid contact with eyes. Wear safety glasses with side shields (or goggles).   |  |
| Hand protection                             | The protective gloves to be used must comply with the specifications of EC Directive 89/686/EEC and the related standard EN374.  |  |
| Skin and body protection                    | No personal respiratory protective equipment normally required.  |  |
| Respiratory protection                      | Wear appropriate thermal protective clothing, when necessary   |  |
| Environmental exposure controls             | Do not allow into any sewer, on the ground or into any body of water   |  |
| General hygiene considerations              | Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this product. Wash hands before breaks and after work. Wear suitable gloves and eye/face protection |  |
| Section 9: Physical and Chemical Properties |  |  |
| Physical state                              | Tablet   |  |
|   | I  |  |



| Description                                     | Prucalopride tablets containing 1 mg prucalopride are white to off-white colored, round biconvex, film-coated tablets debossed with "76" on one side and "V1" on other side.  They are supplied as:  HDPE bottle of 30 tablets, with child-resistant closure NDC 31722-391-30  Prucalopride tablets containing 2 mg prucalopride are yellow colored, round biconvex film-coated tablets debossed with "77" on one side and "V1" on other side. They are supplied as:  HDPE bottle of 30 tablets, with child-resistant closure NDC 31722-392-30 |
|---|--|
| Sec   | tion 10: Stability and Reactivity  |
| Reactivity                                      | No information available. Chemical stability Stable under normal conditions. Possibility of hazardous reactions None under normal processing. Conditions to avoid None known based on information supplied. Incompatible materials None known based on information supplied. Hazardous decomposition products None known based on information supplied.  |
| Secti   | on 11: Toxicological Information   |
| Information on likely route Product Information | s of exposure  |
| Inhalation                                      | Specific test data for the substance or mixture is not   |
|   | available  |
| Eye contact                                     | Specific test data for the substance or mixture is not available   |
| Skin contact                                    | Specific test data for the substance or mixture is not available.  |
| Ingestion                                       | Specific test data for the substance or mixture is not available. Harmful if swallowed. (based on components).   |

| A |   |   |   |    |
|---|---|---|---|----|
| Λ |   | n | 0 | (2 |
|   | Ш | П | U | IO |

| Symptoms related to the physical, chemical and toxicological characteristics |   |  |
|--|---|--|
| Symptoms :   | No information available  |  |
| Acute toxicity   | Numerical measures of toxicity  |  |
|  | No information available  |  |
| Delayed and immediate effects as well a                                      | s chronic effects from short and long-term exposure   |  |
| Skin corrosion/irritation  | No information available  |  |
| Serious eye damage/eye irritation  | No information available.   |  |
| Respiratory or skin sensitisation  | No information available  |  |
| Germ cell mutagenicity   | No information available  |  |
| Carcinogenicity  | No information available  |  |
| Reproductive toxicity  | No information available  |  |
| STOT - single exposure   | No information available  |  |
| STOT - repeated exposure   | No information available  |  |
| Aspiration hazard  | No information available  |  |
| Section 1  | 12: Ecological Information  |  |
| Ecotoxicity  | Harmful to aquatic life with long lasting effects.  |  |
| Persistence and degradability  | No information available  |  |
| Bioaccumulation  | No information available  |  |
| Mobility in soil   | No information available  |  |
| Other adverse effects  | No information available  |  |
| Section 1  | 3: Disposal Considerations  |  |
| Disposal Methods   |   |  |
| Waste from residues/unused products  | Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation. |  |
| Contaminated packaging   | Do not reuse empty containers.  |  |
| Section 1  | 4: Transport Information  |  |
| TDG  | Not regulated   |  |
| DOT  | Not regulated   |  |



#### **Section 15: Regulatory Information**

## Safety, health and environmental regulations/legislation specific for the substance or mixture

#### International Regulations

The Montreal Protocol on Substances that Deplete the Ozone Layer Not applicable

The Stockholm Convention on Persistent Organic Pollutants Not applicable

The Rotterdam Convention Not applicable

#### International Inventories

| TSCA          | Complies under research and development exemption or |
|---------------|--|
|               | is regulated by a different government agency        |
| DSL/NDSL      | Contact supplier for inventory compliance status     |
| EINECS/ELINCS | Contact supplier for inventory compliance status     |
| ENCS          | Contact supplier for inventory compliance status     |
| IECSC         | Contact supplier for inventory compliance status     |
| KECL          | Contact supplier for inventory compliance status     |
| PICCS         | Contact supplier for inventory compliance status     |
| AIIC          | Contact supplier for inventory compliance status     |
|               |  |

### Section 16: Other Information, including date of preparation or last revision

Issue Date: 20-06-2025

Version: 00

**Further information** 

**Revision date: Nil** 

**Revision note: Nil** 

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Annora Pharma Private Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Annora Pharma Private Limited reserves the right to revise this SDS.